Argos Therapeutics Inc fka ARGSQ

[Schnauzer1]

Also it is interesting that this is not truly a blinded study. Although the insiders promised monitoring committee not to look. That does not explain why insiders hold 60% of shares and are acquiring more as P3 approaches third interim. While suspicious, I would not invest based upon those facts. Rather consider the head and shoulders clearance likely hood this P3 has of passage. Once monitoring committee pass on third interim this stock is truly going to become unattainable at any reasonable price, given the float is only 9.5m. Heck yesterday's volume was almost equivalent to 10% float. Poor shorts were at 1.0m. Time to cover is way past due. But question is, have they, covered?